首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到17条相似文献,搜索用时 140 毫秒
1.
目的:评价兰索拉唑、阿莫西林联合用药方案对幽门螺旋杆菌(Hp)所致十二指肠溃疡(DU)的治疗效果及用药安全性。方法:选择我院确诊、治疗的70例DU患者(Hp检查均呈阳性),应用随机数表法将其分为观察组(35例,服用兰索拉唑+阿莫西林)、对照组(35例,服用贝雷拉唑+阿莫西林),对比两组的临床疗效、随访复发情况、用药不良反应。结果:治疗1疗程后,观察组的痊愈率、Hp根除率均显著高于对照组(P<0.05)、不良反应率显著低于对照组(P<0.05);在随访1年期间,与对照组相比,观察组痊愈病例的复发率更低(P<0.05)。结论:兰索拉唑、阿莫西林联合疗法可有效根除Hp、降低溃疡复发率,对于Hp相关性十二指肠溃疡的临床疗效良好,且不良反应少,值得推广应用。  相似文献   

2.
江炬 《现代医院》2009,9(7):13-14
目的探讨兰索拉唑、克拉霉素、甲硝唑三联疗法治疗幽门螺杆菌相关性溃疡病的效果。方法对51例确诊为幽门螺杆菌(Hp)感染的胃溃疡、十二指肠溃疡患者利用兰索拉唑、克拉霉素、甲硝唑三联疗法进行治疗,观察溃疡愈合情况及Hp根除情况。结果本疗法对溃疡的总有效率为90%,Hp根除率为88%。结论兰索拉唑、克拉霉素、甲硝唑三联疗法治疗幽门螺杆菌相关性溃疡具有药物剂量小、Hp根除率高、溃疡愈合迅速、疗程短等优点,值得在临床上推广应用。  相似文献   

3.
唐厚忠 《中国保健》2008,16(4):118-120
目的:观察兰索拉唑、硫糖铝、呋喃唑酮三联疗法对幽门螺杆菌(Hp)的根除效果及消化性溃疡(PU)的治疗效果.方法:对142例幽门螺杆菌阳性的消化性溃疡,随机分为治疗组和对照组.治疗组72例,给予兰索拉唑15mg,每日2次;呋喃唑酮100mg,每日2次;硫糖铝1000mg,每日3次;饭前服用,疗程2w.对照组70例,给予胶体果胶铋100mg,每日3次;硫糖铝1000mg,每日3次;呋喃唑酮100mg,每日2次;饭前服用,疗程2w.停药4w后复查胃镜.结果:治疗组与对照组Hp根除率分别为93.9%、53.5%,有显著差异(P<0.05);溃疡愈合率分别为97.22%、77.14%,有显著差异(P<0.05).结论:兰索拉唑、硫糖铝、呋喃唑酮三联疗法具有疗程短、疗效高,依从性好、治疗中无明显不良反应,值得推广应用.  相似文献   

4.
目的观察兰索拉唑联合甲硝唑和阿莫西林对对消化性溃疡(PU)的治疗以及幽门螺杆菌(Hp)的根除效果。方法将62例患者,随机分为两组,其中治疗组31例,给予兰索拉唑,甲硝唑和阿莫西林,饭前服用10天;对照组31例,给予法莫替丁,甲硝唑和阿莫西林,饭前服用10天,两组治疗期间不加用其他胃药。停药4周后复查胃镜,并进行尿素酶试验。结果治疗组溃疡愈合率为93.5%,对照组溃疡愈合率为67.7%,差异有显著性(P<0.05);治疗组幽门螺杆菌根除率为87.1%,对照组幽门螺杆菌根除率为58.1%,差异有显著性(P<0.05)。结论兰索拉唑联合甲硝唑和阿莫西林是治疗幽门螺杆菌阳性的消化性溃疡的理想药物。  相似文献   

5.
黄孝营  汪孝群 《现代预防医学》2006,33(12):2485-2486
目的:评价丽珠维三联(Lizhuwei Sanlian)联合兰索拉唑(Lansoprazole)根除幽门螺杆菌(Hp)和治疗相关性消化性溃疡(peptic ulcer,PU)的效果.方法:将61例Hp相关性PU患者随机分为丽珠维三联+兰索拉唑组(A组):橼酸镁铋钾,替硝唑,克拉霉素,兰索拉唑,连续1周;B组:兰索拉唑,阿莫西林,甲硝唑,连续2周;疗程结束后继续服用兰索拉唑到4周.停药4周后复查电子胃镜及14C呼吸实验.结果:A组Hp根除率96.7%明显高于B组的83.9%(P<0.05);A组的溃疡愈合率90.0%、总有效率96.7%,高于B组83.9%、90.3%,;两组均无明显副作用.结论:丽珠维三联联合兰索拉唑能有效根除Hp,对PU有较高的治愈率和症状缓解率,且副作用小.  相似文献   

6.
目的 研究根除幽门螺杆菌(Hp)治疗对Hp阳性的十二指肠球部溃疡愈合率、愈合质量及复发的影响.方法 将78例Hp阳性的十二指肠球部溃疡患者随机分为除菌组和非除菌组,除菌组给予泮托拉唑40 mg+克拉霉素0.5 g+呋喃唑酮0.1 g口服,2次/d,1周后泮托拉唑改为40mg,1次/d,共治疗6周.非除菌组单独给予泮托拉唑,剂量方法同上.分别于6周及1年后复查胃镜.结果 除菌组和非除菌组比较,6周后溃疡愈合率差异无统计学意义(分别为97.6%和91.7%,P>0.05).6周后溃疡愈合质量比较差异有统计学意义.1年后两组溃疡复发率比较,除菌组低于非除菌组,差异有统计学意义(分别为6.7%和59.3%,P<0.01),Hp根除率除菌组高于非除菌组,差异有统计学意义(分别为86.7%和3.7%,P<0.01).结论 Hp感染与十二指肠球部溃疡存在相关性,根除Hp治疗不仅可以提高溃疡的愈合质量,而且还可以减少溃疡的复发.  相似文献   

7.
消化性溃疡的药物治疗比较分析   总被引:4,自引:1,他引:3  
目的观察兰索拉唑,阿莫西林,克拉霉素,枸橼酸铋钾四联疗法根除幽门螺杆菌的疗效。方法选择62例Hp阳性消化性溃疡患者,随机分为治疗组31例,对照组31例。治疗组采用兰索拉唑(30mg,1次/d)加阿莫西林(1000mg,2次/d)加克拉霉素(500mg,2次/d)加枸橼酸铋钾(4000mg,4次/d)进行治疗。对照组采用雷尼替丁(300mg,睡前一次服用)加阿莫西林(1000mg,2次/d)加克拉霉素(500mg,2次/d)进行治疗。疗程结束4周后复查胃镜和Hp检查,并观察总有效率和Hp根除率。结果治疗组和对照组的总有效率分别为93.3%和77.4%,两组比较差异有显著性,P<0.025。两组的Hp根除率分别为83.9%和66.7%,两组比较差异有显著性,P<0.01。结论兰索拉唑,阿莫西林,克拉霉素,枸橼酸铋钾四种药物合用,Hp根除率优于对照组,能有效控制消化性溃疡,促进愈合,安全且耐受性好,是一种较为理想的治疗方案。  相似文献   

8.
两种四联疗法治疗幽门螺杆菌阳性消化性溃疡疗效比较   总被引:1,自引:0,他引:1  
目的 对两种四联疗法根除幽门螺杆菌(Hp)和治疗消化性溃疡的疗效进行对比分析.方法 78例Hp阳性的消化性溃疡患者运用随机数字表法分为A、B两组(A组40例,B组38例),分别服用呋喃唑酮、左氧氟沙星,两组均同时加用兰索拉唑、枸橼酸铋钾及阿莫西林,疗程2周.记录治疗期间发生的不良反应.疗程结束1个月后,以14C-尿素呼气试验(14C-UBT)和胃镜观察Hp根除情况、溃疡愈合情况.结果 A、B两组的Hp根除率分别为95.0%(38/40)和92.1%(35/38),两组比较差异无统计学意义(P>0.05);溃疡愈合率分别为97.5%(39/40)和97.4%(37/38),两组比较差异无统计学意义(P>0.05).结论 两种方案在根除Hp及治疗溃疡上疗效相同,是治疗Hp阳性的消化性溃疡可供选择的方法之一.  相似文献   

9.
目的比较使用不同质子泵抑制剂(奥美拉唑、兰索拉唑和埃索美拉唑)三联疗法治疗幽门螺杆菌阳性消化性溃疡的疗效。方法将内镜诊断为幽门螺杆菌阳性的消化性溃疡患者120例分为以下三组:①奥美拉唑三联疗法组40例;②兰索拉唑三联疗法组40例;③埃索美拉唑三联疗法组40例。用药结束1个月后复查胃镜,检测幽门螺杆菌。结果奥美拉唑、兰索拉唑和埃索美拉唑治疗组的溃疡愈合率分别为75.0%、80.0%和92.5%;治疗总有效率分别为90.0%、92.5%和97.5%。埃索美拉唑治疗组的溃疡愈合率及治疗总有效率均明显高于其它两组,奥美拉唑治疗组和兰索拉唑治疗组的溃疡愈合率及治疗总有效率没有明显差异。奥美拉唑、兰索拉唑和埃索美拉唑治疗组的幽门螺杆菌根除率分别为70.0%、77.5%和87.5%,埃索美拉唑治疗组的幽门螺杆菌根除率明显高于其它两组,奥美拉唑治疗组和兰索拉唑治疗组的幽门螺杆菌根除率没有明显的统计学差异。结论三组三联疗法方案均能有效治疗消化性溃疡,并有效地根除幽门螺杆菌,但埃索美拉唑三联疗法的效果明显优于其它两种方案。  相似文献   

10.
目的 观察雷尼替丁枸橼酸钠、克拉霉素、呋喃唑酮三联短程疗法对十二指肠溃疡的治疗结果及对幽门螺旋杆菌的根除效果。方法 幽门螺旋杆菌阳性的活动性十二指肠溃疡患者66例,随机分为治疗组和对照组。治疗组给予雷尼替丁枸橼酸钠400mg、克拉霉素500mg、呋喃唑酮100mg每日2次口服。对照组给予兰索拉唑30mg、克拉霉素500mg、呋喃唑酮100mg每日2次口服。饭前服用1周,停药4周后复查胃镜。结果 治疗组与对照组幽门螺旋杆菌根除率分别为90.9%、87.8%,无显著性差异(P〉0.05);溃疡愈合率分别为93.9%、90.9%,无显著性差异(P〉0.05)。结论雷尼替丁枸橼酸钠、克拉霉素、呋喃唑酮是治疗幽门螺旋杆菌阳性的活动性十二指肠溃疡的最佳选择之一。  相似文献   

11.
The aim of this study was to compare in an open, controlled and prospective trial the efficacy of one-week regimen using either lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I, 60 cases) or ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II, 61 cases) on the eradication of Hp infection in duodenal ulcer patients. The diagnosis was stated endoscopically. Hp infection was confirmed from 2 antral + 2 corporeal biopsies by the modified Giemsa stain and rapid urease test. After eradication the patients were given on-demand treatment with 30 mg lansoprazole (group I) or 2 x 150 mg ranitidine (group II). Control 13C-urea breath test was performed 4-6 weeks after eradication. On intention to treat basis, Hp was eradicated in 78.3% (confidence interval, CI: 67.6-89.1%) in group I and 78.7% (CI: 68.1-89.2%) in group II (p > 0.05). Per protocol eradication rates were 92.1% (CI: 84.5-99.7%) in group I and 90.5 (CI: 82.4-98.6%) in group II (p > 0.05). Side effects were recorded in 13.5% in group I and 18.3% of cases in group II. Short term triple therapies using either lansoprazole or ranitidine bismuth citrate + 2 antimicrobials were effective and safe in the eradication of Hp in duodenal ulcer patients.  相似文献   

12.
目的:探讨不同疗程的三联疗法对溃疡愈合率和幽门螺杆菌旧日的根除率是否有影响。方法:45例经胃镜确诊的十二指肠溃疡患者,经胛检查阳性。随机分成两组进行治疗,采用埃索美拉唑,阿莫西林及克拉霉素的三联疗法。A组为埃索美拉唑每日20mg,晨起空腹服用,服6周,阿莫西林1000mg,每日2次;克拉霉素500mg,每日2次,两者均服用1周;B组埃索美拉唑用法一样,而阿莫西林及克拉霉素的疗程为2周。两组均于治疗结束后4周复查胃镜,观察溃疡愈合率,并重复HP检查,观察HP根除率。结果:A组23例,溃疡愈合21例,愈合率91.3%,HP根除20例,HP根除率为86.9%;B组22例,溃疡愈合20例,愈合率90.9%,HP根除19例,删’根除率为86.4%。两者无论是溃疡愈合率还是日P根除率均没有明显差别,在统计学中的差异无显著意义。结论:以埃索美拉唑为基础的三联疗法中,阿莫西林及克拉霉素应用的时间不同对疗效无明显影响。  相似文献   

13.
[目的]探讨兰索拉唑治疗十二指肠溃疡的临床疗效。[方法]采用以质子泵抑制剂兰索拉唑为主要治疗药物的综合治疗方案治疗十二指肠溃疡,并与采用雷尼替丁治疗的对照组进行临床疗效和不良反应比较研究。[结果]治疗组患者中愈合32例,占88.89%,显效3例,占8.33%,有效1例,占2.78%,总有效率达100.00%;经统计分析发现治疗组的愈合率和总有效率均明显高于对照组,差异有统计学意义(P﹤0.05)。另外,36例治疗组中有33例患者的HP检查呈阴性,占91.67%;36例对照组中有28例患者的HP检查呈阴性,占77.78%,两组比较有明显差异,差异有统计学意义(P﹤0.05)。治疗组中出现口苦2例,便秘3例;对照组中口苦2例,腹胀2例;两组患者未出现其他严重的不良反应。两组比较差异无统计学意义(P﹥0.05)。[结论]在抗Hp及保护胃黏膜等常规治疗基础上加用兰索拉唑治疗活动性十二指肠溃疡显示出良好的临床效果,对十二指肠溃疡的愈合率及总有效率优于雷尼替丁,该药疗效好,且具有疗程短和Hp根除率高,安全性好,患者耐受性好等优点,值得临床推广应用。  相似文献   

14.
We report the incidence of peptic ulcers (duodenal, pyloric canal, gastric, and combined) verified by radiologic, endoscopic, or surgical evidence in a large Health Maintenance Organization (HMO) in Los Angeles, California. For members age 15 and above, the peptic ulcer incidence rate was 0.86 per 1,000 person-years (p-y) (males 1.10, females 0.63). The male to female sex ratio was 1.7. Two hundred twenty-two duodenal, 17 pyloric canal, 89 gastric, and 21 combined first-time diagnosed ulcer cases were located. For duodenal and pyloric canal ulcer, the incidence rate for members age 15 and above was 0.58 per 1,000 p-y (males 0.76, females 0.40). For gastric ulcer, the incidence rate for members age 15 and above was 0.21 per 1,000 p-y (males 0.23, females 0.18). The combined ulcer rate was 0.05 per 1,000 p-y (males 0.07, females 0.02). Gastric ulcer rates were two times higher in 1980 than in 1977. Peptic ulcer age-specific incidence rates increased with age. Incidence rates were much lower than those reported in previous studies, but the gastric to duodenal ulcer ratio and the age and sex relation to ulcer incidence were similar to those previously reported.  相似文献   

15.
Perforated duodenal ulcer and cigarette smoking.   总被引:1,自引:0,他引:1       下载免费PDF全文
Whilst the association between smoking and peptic ulceration has been reported previously, the relationship between smoking and the complications of ulcers, such as perforation, bleeding or acute painful exacerbation, has not been examined. In a retrospective study comparing 275 emergency admissions for peptic ulcer with 275 controls, cigarette smoking was significantly more common only in those with a perforated duodenal ulcer. Of 128 patients with perforated duodenal ulcers, 110 (86%) were cigarette smokers compared with 65 (51%) of the 128 matched controls (X2, P less than 0.01). Cigarette smoking in patients with bleeding or acutely exacerbated ulcers was not significantly more common than in controls. These findings strongly suggest a particular association between smoking and perforated duodenal ulcer.  相似文献   

16.
The authors' aim in this study was to explore the prevalence, symptomatology, and risk factors for peptic ulcer in a general adult population. Between December 1998 and June 2001, the authors surveyed a random sample (n=3,000) of the adult population (n=21,610) in two communities in northern Sweden using a validated questionnaire, the Abdominal Symptom Questionnaire (response rate=74%). A subsample (n=1,001) of the responders was randomly invited to undergo esophagogastroduodenoscopy and symptom assessment (response rate=73%). The prevalence of peptic ulcer was 4.1% (20 gastric ulcers and 21 duodenal ulcers). Nausea and gastroesophageal reflux were significant predictors of peptic ulcer disease, but epigastric pain/discomfort was not. Six persons with gastric ulcer and two persons with duodenal ulcer were asymptomatic. Eight subjects with duodenal ulcer (38%) lacked evidence of current Helicobacter pylori infection. Five (25%) of the gastric ulcers and four (19%) of the duodenal ulcers were idiopathic (no use of aspirin or nonsteroidal antiinflammatory drugs, no H. pylori infection). Smoking, aspirin use, and obesity were risk factors for gastric ulcer; smoking, low-dose (相似文献   

17.
廖怀强  刘建坤 《医疗保健器具》2011,18(11):1755-1756
目的分析并评价联合使用铝碳酸镁以及兰索拉唑对胃溃疡的临床疗效。方法将我院自2009年10月至2010年12月期间收治的86例活动性胃溃疡病人随机分成观察组及对照组各43例,两组均先实施幽门螺杆菌根除的三联疗法,给予60mg/d兰索拉唑+800mg/d甲硝唑+500mg/d克拉霉素。治疗二周后,观察组在给予40mg/d兰索拉唑的同时再给予铝碳酸镁;对照组仅给予40mg/d兰索拉唑,口服。全部病人均连续给药8周。结果观察组的痊愈率(60.5%)高于对照组的痊愈率(30.2%),两组对比差异显著(P〈0.05),具统计学意义;观察组的总有效率(88.4%)高于对照组的总有效率(67.4%),两组对比差异显著(P〈0.05),具统计学意义,两组均无明显的不良反应发生。结论联合使用兰索拉唑与铝碳酸镁对胃溃疡的临床治疗效果明显优于单独使用兰索拉唑,是一种治疗胃溃疡安全且有效的方法,值得临床广泛推广。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号